Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KISLip is a consumer health supplement developed by PICO Entech, a South Korean biotechnology company. It is formulated with aldehyde dehydrogenase (ALDH) enzyme derived from yeast-fermented powder and fermented rice extract using the company's proprietary ARC (ALDH Related Compounds) fermentation technology. KISLip is primarily marketed for hangover relief, functioning by accelerating the metabolic breakdown of alcohol and its toxic byproduct, acetaldehyde, in the body. Clinical studies have indicated that KISLip reduces blood alcohol and acetaldehyde levels in a dose-dependent manner, thereby mitigating hangover symptoms. While PICO Entech also utilizes its ALDH technology in cosmetic products, KISLip is specifically recognized as the world's first commercialized edible ALDH supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KISLip.